Authors

US-Cuban Partnership Developing Anticancer Vaccine for NSCLC

Leaders of Roswell Park Cancer Institute (RPCI) in Buffalo, New York, have agreed to collaborate with the Center for Molecular Immunology (CIM) in Cuba to evaluate a therapeutic anticancer vaccine for non–small cell lung cancer (NSCLC) in the United States.

Riding the Wave of Chemoimmunotherapy: A New Era in Endometrial Cancer Management

Expanded Guidelines Offer Clearer Diagnosis for Classical, Special Variants of CMML

Recent guidelines highlight the need to distinguish chronic myelomonocytic leukemia from conditions similar to other myeloproliferative neoplasms, provide standardized diagnostic procedures, and outline therapeutic options for adult patients with CMML.

Debating the True Benefit of Adjuvant TKIs in High-Risk RCC

Adjuvant therapy with TKIs for patients with high-risk renal cell carcinoma who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines, yet this approach is still controversial, with many physicians believing that there are not yet enough data in support of its use. 

Tumor Antigens and Their Role in Immune Response in Melanoma

Melanoma is the most deadly skin cancer. According to data collected between 2004 and 2010, only 16% of Americans with metastatic melanoma, including people of all ages and races, and both genders, survive for 5 years or more after diagnosis.

Chronic Lymphocytic Leukemia Treatment Evolving With Some Challenges

Where once limited treatment options existed for patients with CLL, medical oncologists now have a plethora of agents from which to choose, making disease management in CLL more effective with fewer toxicities.

Oncolytic Vaccines With Chemotherapy Show Survival Benefit in Head and Neck Cancer

The attenuated vaccinia virus, GL-ONC1, demonstrated safety and clinical benefit when delivered intravenously with concurrent chemoradiation therapy in patients who have locoregionally advanced head and neck carcinoma (LA-HNC).

Subsets of Patients With NETs Show Better Response to Cabozantinib

Lowell B. Anthony, MD, discusses the potential benefits of cabozantinib for patients for different types of patients with neuroendocrine tumors.

New Research to Identify Chemo-Resistant Genes in Ovarian Cancer

Research may hasten the effort to determine which strains of cancer will eventually become resistant to chemotherapy, paving the way for developing more effective targeted treatments.

Next Generation Novel Agents for Aggressive B-Cell Lymphoma

A SOHO 2022 presentation by Jason Westin, MD will focus on t on 2 main categories of novel agents that manipulate the immune system to better target aggressive lymphomas.

The Role of In-Office Next Generation Sequencing to Advance Precision Medicine in Community Oncology

The goal of precision medicine is to advance medical and scientific discoveries to offer more tailored, precise, and accurate health interventions to maximize the health benefits for patients.

The Utility of Pomalidomide in R/R Multiple Myeloma

Manish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.

T-Cell–Redirecting Strategies Emerge in Myeloma From 2025 ASCO, EHA, and IMS

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

Diagnostic Platforms for Lung Cancer

Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses diagnostic platforms for lung cancer.

Immune Checkpoint Inhibitors Approach Frontline Setting in Head and Neck Squamous Cell Cancer

Immune checkpoint inhibitors as monotherapy and in combinations regimens are producing promising efficacy data in metastatic head and neck cancers, depite struggles in finding the right treatment settings and patient population subsets.

SHP2 Inhibitors Open the Door to Treat KRAS-Mutant Cancers

Agents that inhibit SHP2 attack cancer cells in a way that is distinct from other therapies, and data showing the potential efficacy of such therapies, are fueling more research.

Study Results Show Multidisciplinary Tumor Boards Lead to Improved OS for HCC Patients

Multidisciplinary tumor boards led to higher utilization of guideline-recommended curative therapies, which was associated with improved overall survival (OS) for patients with early-stage hepatocellular carcinoma.

Current Systemic Management of Pleural Malignant Mesothelioma

Malignant mesothelioma is an uncommon malignancy of the pleura that is usually associated with asbestos exposure.

Immunotherapy in GU Cancers

Mark A. Rubin, MD, director, Institute for Precision Medicine, Weill Cornell Medical College, discusses immunotherapy in the field of genitourinary cancers.

KRAS and Outcomes in Pancreatic Cancer

Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.

A Bispecific Immunotherapy for the Treatment of Melanoma

Mark R. Middleton, MD, PhD, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.

BTK and PI3K Inhibitors in Development for Chronic Lymphocytic Leukemia

Mark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia.

Results of the SELECT Trial in Thyroid Cancer

Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.

After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?

Targeted Therapies in Oncology spoke with Martin J. Edelman, MD, do uncover what is next for small cell lung cancer after PD-1 inhibitor indication have been withdrawn.